Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash & Current Investments (2016 - 2026)

OptimizeRx's Cash & Current Investments history spans 16 years, with the latest figure at $23.4 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments rose 74.63% to $23.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.4 million, a 74.63% increase, with the full-year FY2025 number at $23.4 million, up 74.63% from a year prior.
  • Cash & Current Investments hit $23.4 million in Q4 2025 for OptimizeRx, up from $19.5 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for OPRX hit a ceiling of $89.0 million in Q1 2022 and a floor of $13.4 million in Q4 2024.
  • Historically, Cash & Current Investments has averaged $50.7 million across 5 years, with a median of $63.1 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: soared 705.21% in 2021 and later crashed 81.32% in 2023.
  • Tracing OPRX's Cash & Current Investments over 5 years: stood at $84.7 million in 2021, then fell by 12.45% to $74.1 million in 2022, then crashed by 81.32% to $13.9 million in 2023, then dropped by 3.41% to $13.4 million in 2024, then soared by 74.63% to $23.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for OPRX at $23.4 million in Q4 2025, $19.5 million in Q3 2025, and $16.6 million in Q2 2025.